Beta Drugs Limited — Results, 19-12-2024: Reply to Clarification- Financial results

Beta Drugs Limited reports a strong performance in its unaudited consolidated financial results for the half-year ended 30th September 2024. Total revenue stands at ₹181.81 crore, reflecting a robust year-over-year growth of approximately 28% compared to ₹141.80 crore for the same period in the previous year. This growth is attributed to increased demand and market expansion in the pharmaceutical sector.

Net profit for the half-year reached ₹24.44 crore, up significantly from ₹19.87 crore in the prior year, demonstrating a year-on-year increase of around 23%. The Earnings Per Share (EPS) has improved to ₹25.42 from ₹17.23, indicating stronger profitability. Key factors influencing profitability include effective cost management and operational improvements, although operational costs increased by 9% due to higher material costs and employee benefits, now totaling ₹149.03 crore.

The balance sheet remains healthy, with total assets amounting to ₹132.36 crore and liabilities well-contained, showing an overall solid financial position. Cash flow from operating activities was positive, further underscoring effective cash management practices.

Looking forward, Beta Drugs Limited appears focused on further growth strategies emphasizing cost control and expansion potential in the pharmaceutical market. Overall, the financial performance suggests a buy insight for investors considering the substantial revenue growth and profitability improvement.